Chartwell Investment Partners LLC Buys 14,477 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Chartwell Investment Partners LLC lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 21.3% during the third quarter, Holdings Channel.com reports. The firm owned 82,410 shares of the company’s stock after acquiring an additional 14,477 shares during the period. Chartwell Investment Partners LLC’s holdings in Amneal Pharmaceuticals were worth $686,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Rothschild Investment LLC bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $26,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $42,000. Atlanta Consulting Group Advisors LLC bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $61,000. nVerses Capital LLC bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at about $62,000. Finally, Bayesian Capital Management LP bought a new position in Amneal Pharmaceuticals in the 1st quarter valued at about $65,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Up 0.5 %

Shares of AMRX stock opened at $9.25 on Wednesday. The company has a 50 day moving average of $8.54 and a 200-day moving average of $7.59. Amneal Pharmaceuticals, Inc. has a 12-month low of $4.15 and a 12-month high of $9.48. The firm has a market cap of $2.86 billion, a P/E ratio of -13.60 and a beta of 1.17.

Analyst Upgrades and Downgrades

AMRX has been the topic of several recent research reports. Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.